158 related articles for article (PubMed ID: 2948969)
1. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate.
Allegra CJ; Kovacs JA; Drake JC; Swan JC; Chabner BA; Masur H
J Clin Invest; 1987 Feb; 79(2):478-82. PubMed ID: 2948969
[TBL] [Abstract][Full Text] [Related]
2. Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii.
Kovacs JA; Allegra CJ; Chabner BA; Swan JC; Drake J; Lunde M; Parrillo JE; Masur H
J Infect Dis; 1987 May; 155(5):1027-32. PubMed ID: 2951446
[TBL] [Abstract][Full Text] [Related]
3. Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate.
Kovacs JA; Allegra CJ; Swan JC; Drake JC; Parrillo JE; Chabner BA; Masur H
Antimicrob Agents Chemother; 1988 Apr; 32(4):430-3. PubMed ID: 2967669
[TBL] [Abstract][Full Text] [Related]
4. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
Piper JR; Johnson CA; Krauth CA; Carter RL; Hosmer CA; Queener SF; Borotz SE; Pfefferkorn ER
J Med Chem; 1996 Mar; 39(6):1271-80. PubMed ID: 8632434
[TBL] [Abstract][Full Text] [Related]
5. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase.
Chio LC; Queener SF
Antimicrob Agents Chemother; 1993 Sep; 37(9):1914-23. PubMed ID: 8239605
[TBL] [Abstract][Full Text] [Related]
6. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent.
Allegra CJ; Kovacs JA; Drake JC; Swan JC; Chabner BA; Masur H
J Exp Med; 1987 Mar; 165(3):926-31. PubMed ID: 2950200
[TBL] [Abstract][Full Text] [Related]
7. In vitro effects of folate inhibitors on Toxoplasma gondii.
Derouin F; Chastang C
Antimicrob Agents Chemother; 1989 Oct; 33(10):1753-9. PubMed ID: 2531568
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia.
Kovacs JA; Allegra CJ; Kennedy S; Swan JC; Drake J; Parrillo JE; Chabner B; Masur H
Am J Trop Med Hyg; 1988 Nov; 39(5):491-6. PubMed ID: 2973755
[TBL] [Abstract][Full Text] [Related]
9. Biochemical pharmacology of the lipophilic antifolate, trimetrexate.
Jackson RC; Fry DW; Boritzki TJ; Besserer JA; Leopold WR; Sloan BJ; Elslager EF
Adv Enzyme Regul; 1984; 22():187-206. PubMed ID: 6236675
[TBL] [Abstract][Full Text] [Related]
10. 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
Rosowsky A; Mota CE; Queener SF; Waltham M; Ercikan-Abali E; Bertino JR
J Med Chem; 1995 Mar; 38(5):745-52. PubMed ID: 7877140
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a localized conversion of endogenous tetrahydrofolate cofactors to dihydrofolate as an important element in antifolate action in murine leukemia cells.
Matherly LH; Muench SP
Biochem Pharmacol; 1990 Jun; 39(12):2005-14. PubMed ID: 2141258
[TBL] [Abstract][Full Text] [Related]
12. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
Diddens H; Niethammer D; Jackson RC
Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
[TBL] [Abstract][Full Text] [Related]
13. Trimetrexate: clinical development of a nonclassical antifolate.
O'Dwyer PJ; DeLap RJ; King SA; Grillo-Lopez AJ; Hoth DF; Leyland-Jones B
NCI Monogr; 1987; (5):105-9. PubMed ID: 2963228
[TBL] [Abstract][Full Text] [Related]
14. 2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
Rosowsky A; Mota CE; Wright JE; Queener SF
J Med Chem; 1994 Dec; 37(26):4522-8. PubMed ID: 7799402
[TBL] [Abstract][Full Text] [Related]
15. 2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Mota CE; Wright JE; Freisheim JH; Heusner JJ; McCormack JJ; Queener SF
J Med Chem; 1993 Oct; 36(21):3103-12. PubMed ID: 8230096
[TBL] [Abstract][Full Text] [Related]
16. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.
Matherly LH; Barlowe CK; Goldman ID
Cancer Res; 1986 Feb; 46(2):588-93. PubMed ID: 2416428
[TBL] [Abstract][Full Text] [Related]
17. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
Galivan J; Nimec Z; Rhee M; Boschelli D; Oronsky AL; Kerwar SS
Cancer Res; 1988 May; 48(9):2421-5. PubMed ID: 2965613
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
Rosowsky A; Papoulis AT; Forsch RA; Queener SF
J Med Chem; 1999 Mar; 42(6):1007-17. PubMed ID: 10090784
[TBL] [Abstract][Full Text] [Related]
19. 6,7-disubstituted 2,4-diaminopteridines: novel inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Jackson HC; Biggadike K; McKilligin E; Kinsman OS; Queener SF; Lane A; Smith JE
Antimicrob Agents Chemother; 1996 Jun; 40(6):1371-5. PubMed ID: 8726003
[TBL] [Abstract][Full Text] [Related]
20. Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells.
Seither RL; Trent DF; Mikulecky DC; Rape TJ; Goldman ID
J Biol Chem; 1989 Oct; 264(29):17016-23. PubMed ID: 2529254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
